Turnstone Biologics Competitor
Turnstone Biologics Corp. is a clinical-stage biotechnology company based in San Diego, California. The company focuses on developing innovative immunotherapies for solid tumors, employing a team of 51 to 200 individuals. Turnstone specializes in Selected TIL therapy, which enhances the identification and expansion of potent tumor-reactive T cells, aiming to improve treatment efficacy across various solid tumors.
The company's lead clinical program, TIDAL-01, was evaluated in Phase 1 studies for several cancer types, including melanoma and breast cancer. Although development of TIDAL-01 has been discontinued, Turnstone is advancing its preclinical Selected TIL program, TIDAL-02. The company is also exploring combination therapies and is open to strategic alternatives to maximize shareholder value, including potential mergers or asset sales. Turnstone promotes a collaborative corporate culture that values scientific rigor and employee development, while also emphasizing inclusive hiring practices.
